• Users Online: 355
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

In silico study of six FDA approved anti-HCV drugs as inhibitors for NS5 methyltransferase of dengue virus type 2


1 Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt
2 Department of Clinical Research and Leadership, School of Medicine and Health Sciences, George Washington University, Washington DC, USA

Correspondence Address:
Aaya M Nassar,
Department of Clinical Research and Leadership, School of Medicine and Health Sciences, George Washington University, Washington DC
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-9062.321755

Background & objectives: Dengue virus infection has become a major health threat. Dengue is a mosquito-borne viral infection caused by a viral RNA of the family Flaviviridae and spread by Aedes mosquitoes. Dengue NS5 methyltransferase is used as a drug target for the disease. Six FDA approved anti-HCV drugs were tested as potential dengue virus type 2 methyltransferase inhibitors using molecular docking analysis seeking potential treatment. Methods: Molecular docking analysis tested six FDA approved anti-HCV drugs, including Elbasvir, Daclatasvir, Ledipasvir, Pibrentasvir, Velpatasvir, and Ombitasvir. Results: 1000 ps molecular dynamics simulation of protein-complex validates its stability. Interpretation & conclusion: The analysis indicates the binding of Ombitasvir with the protein drug target with optimal binding features for further in vitro and in vivo evaluations. Ombitasvir was the optimum candidate ligand compound with binding affinity value (-11.56 ΁ 0.46 kcal/mol) with 2P3Q. Interactions of Ombitasvir with the active site residues of 2P3Q revealed good results for experimental drug testing.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Khater IM
    -  Nassar AM
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed31    
    PDF Downloaded0    

Recommend this journal